Oxybutynin Chloride in Managing Hot Flashes

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions
Breast CarcinomaDuctal Breast Carcinoma In SituHot FlashesLobular Breast Carcinoma In SituNo Evidence of Disease
Interventions
DRUG

Oxybutynin Chloride

Given PO

OTHER

Placebo

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (13)

27518

Waverly Hematology Oncology, Cary

29621

AnMed Health Cancer Center, Anderson

41017

Saint Elizabeth Medical Center South, Edgewood

48106

Michigan Cancer Research Consortium NCORP, Ann Arbor

52403

Oncology Associates at Mercy Medical Center, Cedar Rapids

53792

University of Wisconsin Hospital and Clinics, Madison

54301

Saint Vincent Hospital -Green Bay, Green Bay

54449

Marshfield Clinic, Marshfield

55905

Mayo Clinic, Rochester

57701

Rapid City Regional Hospital, Rapid City

61615

Illinois CancerCare-Peoria, Peoria

61801

Carle Cancer Center NCI Community Oncology Research Program, Urbana

67214

Cancer Center of Kansas - Wichita, Wichita

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER

NCT02961790 - Oxybutynin Chloride in Managing Hot Flashes | Biotech Hunter | Biotech Hunter